Department of Obstetrics and Gynecology, Hospital del Mar, Barcelona, Spain.
J Affect Disord. 2012 Dec 10;141(2-3):120-9. doi: 10.1016/j.jad.2012.01.043. Epub 2012 Feb 25.
Psychiatric illnesses, particularly depression, are some of the most common complications of pregnancy. Accordingly, pharmacologic treatment of these illnesses is prevalent and increasing. Systematic reviews on psychiatric medication use during pregnancy have shown effects on obstetrical and neonatal outcomes and non-systematic reviews of maternal outcomes suggest higher weight gain and an increased risk of gestational diabetes. However, to date there has not been a systematic review of the effects of these medications on maternal metabolic outcomes.
The objective of this study was to assess the relationship between psychiatric medication use during pregnancy and adverse maternal metabolic outcomes [gestational weight gain (GWG), gestational diabetes (GDM) and postpartum weight retention (PPWR)].
Systematic review and meta-analysis were used. We searched Medline, EMBASE, PsychInfo and references. Two reviewers independently performed each step of the systematic review, following the MOOSE guidelines.
Of 3080 non-duplicate titles and abstracts, 175 articles underwent full text review. Two moderate quality cohort studies were included. No differences were found for GWG, GDM and PPWR.
There were only two studies which met our inclusion criteria, making it difficult to make any definitive conclusions regarding the effects of psychiatric medication on maternal metabolic outcomes.
Despite the suggestions in non-systematic reviews that psychiatric medication use during pregnancy results in adverse maternal metabolic sequelae, in this systematic review, we found no evidence of an increased risk of GWG, GDM or PPWR in women with psychiatric illness who took psychiatric medications compared to non-medicated women with psychiatric illness. However, more, high quality studies are needed in this area to determine if there is an association between psychiatric medication use and maternal metabolic outcomes.
精神疾病,尤其是抑郁症,是妊娠最常见的并发症之一。因此,这些疾病的药物治疗很常见且呈上升趋势。对妊娠期间使用精神药物的系统评价显示对产科和新生儿结局有影响,而非系统评价的母亲结局表明体重增加更多和妊娠糖尿病风险增加。然而,迄今为止,还没有对这些药物对母亲代谢结局的影响进行系统评价。
本研究旨在评估妊娠期间使用精神药物与不良母亲代谢结局(妊娠体重增加(GWG)、妊娠糖尿病(GDM)和产后体重滞留(PPWR))之间的关系。
使用系统评价和荟萃分析。我们搜索了 Medline、EMBASE、PsychInfo 和参考文献。两位审查员独立按照 MOOSE 指南执行系统评价的每个步骤。
在 3080 篇非重复标题和摘要中,有 175 篇文章进行了全文审查。纳入了两项中等质量的队列研究。GWG、GDM 和 PPWR 无差异。
仅有两项符合我们纳入标准的研究,因此很难就精神药物对母亲代谢结局的影响得出任何明确的结论。
尽管非系统评价表明妊娠期间使用精神药物会导致母亲代谢不良后果,但在本系统评价中,我们没有发现患有精神疾病的女性在使用精神药物时与未使用药物的女性相比,GWG、GDM 或 PPWR 的风险增加。然而,在这一领域需要更多高质量的研究来确定精神药物使用与母亲代谢结局之间是否存在关联。